Announced Tue, 30 Jun · 16:49 IST
Corona Remedies starts commercial production at new women's hormone facility
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.9%1-day move
₹1967.80
prior close
₹1997.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.6-0.6-0.5-0.7+1.9+3.7+1.8+0.6+0.9+3.9+3.5———
Up moveDown movePending
AI summary
Corona Remedies has commenced commercial production at its new EU-GMP approved Women's Hormone manufacturing facility at Bhayla, Ahmedabad. Spread across 1.0 lakh sq ft, it has annual capacity of 194 million tablets/capsules and 1.5 million ointments/gels. The plant supports tablets, soft gel capsules, ointments and gels, and is expected to boost in-house hormone manufacturing capacity by around 20 percent.
Likely market impact
New facility adds around 20 percent to in-house hormone capacity, supporting future revenue growth and export potential in women's healthcare.